Komori
KYORIN Pharmaceutical (4569) · RiskReframedLatest Financial results briefing materials (2026-05-12): "Worsened"

Intensifying Competition in the Pharmaceutical Industry

First written in FY2017. 2 of 5 entries say "Restated". Latest entry: 2026-05-12.

5entries
10years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY2019ReframedFY20242017: 120172018: 120182019: 120192020: 020202021: 020212022: 020222023: 020232024: 120242025: 020252026: 12026
Same theme, other companies
Loss of Competitiveness Due to Intensifying Competition and Technological Innovation in the Pharmaceutical IndustryA theme 18 companies write about · 19 as a headwind · 0 as a tailwind

KYORIN Pharmaceutical moved to the "Worse" side of this theme in 2024, 5 years after the typical company in this theme (2019).

The whole theme swung hardest in 2022: 5 of 10 companies on the "Worse" side.

3 other companies' latest entry also says "Worsened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 18 companies compared. The sentences above are computed from all 18.
Full recordFilings, disclosures and news, newest first
  1. 2026-05-12WorsenedFinancial results briefing materials

    「We anticipate lower revenue due to lower Desalex sales following generic drug entry, among other factors.」

    Generic drug entry was specifically cited as a reason for lower Desalex sales and the forecast decline in revenue for the fiscal year ending March 2027.
  2. FY2024ReframedAnnual report

    「Competition in the pharmaceutical market is intense. If competition with other products in the same field, the entry of generic drugs after patents for originator drugs expire, and entry by companies from other industries leveraging advanced technologies intensify, this could materially affect the operating performance and financial condition of the Company Group.」

    The description of competitive risks has been structured to include competition from products in the same field and generic entry, as well as entry by companies from other industries with advanced technologies.
  3. FY2019RestatedAnnual report

    「The development of more useful pharmaceuticals and the launch of pharmaceuticals with similar efficacy could affect sales trends for the Company Group's major products.」

    The risk of an impact on sales of major products from technological innovation and the launch of competing products continues to be disclosed.
  4. FY2018RestatedAnnual report

    「The development of more useful pharmaceuticals and the launch of pharmaceuticals with similar efficacy could affect sales trends for the Company Group's major products.」

    The risk of an impact on sales of major products from technological innovation and the launch of competing products continues to be disclosed.
  5. FY2017First statedAnnual report

    「The pharmaceutical industry operates in an environment of rapid technological innovation and progress. The development of more useful pharmaceuticals and the launch of products with similar indications could affect sales trends for the Group’s core products.」

    Technological innovation and the launch of competing products are identified as risks to sales of core products.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet. It last moved in the Financial results briefing materials of 2026-05-12: "Worsened".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Intensifying Competition in the Pharmaceutical Industry | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori